secwatch / observer

8-K filed January 8, 2025, 6:59 PM ET ticker JSPR CIK 0001788028

other material confidence high sentiment positive materiality 0.85

Jasper reports positive BEACON data: 240mg dose shows UAS7 drop of 26.6, 100% complete response at 8 weeks

Jasper Therapeutics, Inc.

Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).
Multiple dosing regimens ≥120mg showed UAS7 reduction >25 points; clinical responses as early as 1 week post-first dose.
Serum tryptase reductions below lower limit of quantification observed; 100% of 240mg cohort at week 1.
Favorable safety profile: no dose-limiting toxicities, infrequent low-grade c-Kit blockade events, no discontinuations.
Registrational Phase 2b study in CSU expected to commence in second half of 2025; additional data by mid-2025.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-001810
form_type: 8-K
ticker: JSPR
cik: 0001788028
company_name: Jasper Therapeutics, Inc.
filed_at: 2025-01-08T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.869440+00:00
generated_at: 2026-05-28T06:57:00.180298+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-001810
json_url: https://secwatch.observer/filing/0001213900-25-001810.json
markdown_url: https://secwatch.observer/filing/0001213900-25-001810.md
text_url: https://secwatch.observer/filing/0001213900-25-001810.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/0001213900-25-001810-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390025001810/ea0227148-8k_jasper.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-25-001810

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.